Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
September 20, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
Aligos Therapeutics
Raised $83.6 million in gross proceeds from common stock offeringSTOPS™ and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoingClinical trial application filed for...
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
July 29, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
June 30, 2021 22:08 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common...
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
June 28, 2021 16:10 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of...
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
June 21, 2021 08:00 ET
|
Aligos Therapeutics
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include nonclinical data from 3 other CHB programs ...
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
June 14, 2021 08:00 ET
|
Aligos Therapeutics
-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being...
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
June 10, 2021 07:00 ET
|
Aligos Therapeutics
Subjects experienced a 2.9 log10 IU/mL mean reduction in HBV DNA levels after 14 days’ dosing with 100 mg ALG-000184 Half (4 out of 8) of these subjects had HBV DNA levels below the lower limit of...
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 20, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
May 10, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...